Biotech
Aug. 28, 2013
The coming scrutiny over doctor pay
The closely intertwined relationships that often exist between doctors and biotechnology companies may soon be viewed in a new light.
Daily Journal Staff Writer
After years of petitioning for more comprehensive oversight into the closely intertwined relationship between doctors and drugmakers, transparency advocates are hailing the newly implemented Physicians Payment Sunshine Act as an essential regulatory tool in the effort to prevent and expose bribery, waste and fraud in the U.S. health care system.
The provisions of the act, which kicked in Aug. 1, r...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In